Search results
Results from the WOW.Com Content Network
And since it split from Abbott in 2013, AbbVie has raised its payout by 288%. The ability to maintain a solid dividend program for years is an incredibly attractive quality to long-term investors.
Pharmaceutical powerhouse AbbVie (NYSE: ABBV) has been a beast since it spun off from Abbott Laboratories in 2012. Over the past decade, the stock has averaged a dividend yield of 3.5% while ...
If you can't decide which dividend investing option you like best, I have some great news. AbbVie has been a long-term dividend investor's dream come true since it split from Abbott Laboratories ...
Before you buy stock in AbbVie, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn’t ...
The selloff in ABBV stock was always a bit overdramatic. The pharma has over 90 therapies under development , over half of them being in mid- to late-stage trials. AbbVie spent $12.8 billion on ...
The contrast between AbbVie's performance and that of the wider market was stark, as the bellwether S&P 500 (SNPINDEX: ^GSPC) sank by a relatively steep 1.5%. Why AbbVie Stock Popped While the ...
A splashy recent acquisition by the company might not be panning out.
The drugmaker has convincingly laid to rest the biggest threat to its top line.